arrow
H

Harriet S. Walter

university of leicester and university hospitals leicester nhs trust
H指数:19
被引数:2,045

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial

Englumafusp alfa联合glofitamab治疗b 细胞非霍奇金淋巴瘤: 1期试验

2026-07-160
OAAI
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study

阿卡巴鲁替尼单药治疗作为CLL的一线治疗:真实世界EPIC研究的3年随访

2026-05-020
OAAI
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology

Experimental Cancer Medicine Centre (ECMC)网络关于泛癌种测序的共识基因面板的提案:一种德尔菲方法

2025-11-080
OAAI
Evaluation of Clinical Parameters Associated with Response and Resistance to Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Retrospective Cohort Study

评估与cemiplimab应答和耐药性相关的临床参数:在局部晚期和转移性皮肤鳞状细胞癌中的多中心回顾性队列研究

2025-03-150
OA
ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies Nishat MSc Sandrine PhD Harriet S. MD PhD MRCP Andrea MD

ASTX295 一种新型强效MDM2拮抗剂在淋巴细胞恶性肿瘤中诱导多种程序性细胞死亡(PCD)机制 Nishat MSc Sandrine PhD Harriet S. MD PhD MRCP Andrea MD

BLOOD
IF23.1
2024-11-050
PRE
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
2024-08-210
OAAI
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK

在英国使用pembrolizumab单药治疗头颈部鳞状细胞癌 (HNSCC)

2024-04-290
OA
Ibrutinib as fi rst-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
2024-03-014
OAAI
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
2022-08-0428
OAAI
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
LEUKEMIA
IF13.4
2020-12-1716
OAAI
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
2020-08-2554
OAAI